HIV/AIDS-related cardiovascular disease

Cardiovascular Toxicology

Volumn 4, Issue 3, 2004, Pages 229-242

  Chaves, Alysia A ^a   Mihm, Michael J ^a   Basuray, Anupam ^a   Baliga, Reshma ^a,c   Ayers, Leona W ^b   Bauer, John A ^a,b,c  

^a THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Cardiovascular; Co infectious pathogens; HIV; Oxidants

Indexed keywords

ABACAVIR; ALPHA INTERFERON; AMPHOTERICIN B; AMPRENAVIR; ANTIFUNGAL AGENT; ASTEMIZOLE; CHLORPROMAZINE; CLARITHROMYCIN; COTRIMOXAZOLE; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ERYTHROMYCIN; IMIPRAMINE; INDINAVIR; INTERLEUKIN 2; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; OXIDIZING AGENT; PENTAMIDINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; THIORIDAZINE; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AIDS RELATED COMPLEX; ANTIVIRAL ACTIVITY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYMPTOM; COMPLEX FORMATION; CONTROLLED STUDY; DRUG INDUCED DISEASE; HEART MUSCLE CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; PATIENT CARE; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SURVIVAL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; ANTI-HIV AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; HIV INFECTIONS; HUMANS; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 6044267988     PISSN: 15307905     EISSN: None     Source Type: Journal    
DOI: 10.1385/CT:4:3:229     Document Type: Review

References (146)

1. CDC. (2001). US HIV and AIDS cases reported through June 2001. HIV AIDS Surveill. Rep. 13.
2. Palella, F.J. Jr., Delaney, K.M., Moorman, A.C., Loveless M.O., Fuhrer, J., Satten, G.A., et al. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338:853-860.
3. Ippolito, G., Galati, V., Serraino, D., and Girardi, E. (2001). The changing picture of the HIV/AIDS epidemic. Ann. NY Acad. Sci. 946:1-12.
4. Antinori, A., Giancola, M.L., Alba, L., Soldani, F., and Grisetti, S. (2001). Cardiomyopathy and encephalopathy in AIDS. Ann. NY Acad. Sci. 946:121-129.
5. Currie, P.F., Jacob, A.J., Foreman, A.R., Elton, R.A., Brettle, R.P., and Boon, N.A. (1994). Heart muscle disease related to HIV infection: prognostic implications. BMJ 309:1605-1607.
6. Felker, G.M., Thompson, R.E., Hare, J.M., Hruban, R.H., Clemetson, D.E., Howard, D.L., et al. (2000). Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N. Engl. J. Med. 342:1077-1084.
7. MMWR. (1981). Pneumocystis pneumonia-Los Angeles. MMWR Morb. Mortal. Wkly. Rep. 30:250-252.
8. Broder, S. and Gallo, R.C. (1984). A pathogenic retrovirus (HTLV-III) linked to AIDS. N. Engl. J. Med. 311:1292-1297.
9. Morris, A., Wachter, R.M., Luce, J., Turner, J., and Huang, L. (2003). Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia. AIDS 17:73-80.
10. Salmon-Ceron, D. (2001). Cytomegalovirus infection: the point in 2001. HIV Med. 2:255-259.
11. Eltom, M.A., Jemal, A., Mbulaiteye, S.M., Devesa, S.S., and Biggar, R.J. (2002). Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998. J. Natl. Cancer Inst. 94:1204-1210.
12. Anderson, D.W., Virmani, R., Reilly, J.M., O'Leary, T., Cunnion, R.E., Robinowitz, M., et al. (1988). Prevalent myocarditis at necropsy in the acquired immunodeficiency syndrome. J. Am. Coll. Cardiol. 11:792-799.
13. Beschorner, W.E., Baughman, K., Turnicky, R.P., Hutchins, G.M., Rowe, S.A., Kavanaugh-McHugh, A.L., et al. (1990). HIV-associated myocarditis. Pathology and immunopathology. Am. J. Pathol. 137:1365-1371.
14. Cammarosano, C. and Lewis, W. (1985). Cardiac lesions in acquired immune deficiency syndrome (AIDS). J. Am. Coll. Cardiol. 5:703-706.
15. Coudray, N., de Zuttere, D., Force, G., Champetier, D.R., Pourny, J.C., Antony, I., et al. (1995). Left ventricular diastolic function in asymptomatic and symptomatic human immunodeficiency virus carriers: an echocardiographic study. Eur. Heart J. 16:61-67.
16. De Castro, S., D'Amati, G., Gallo, P., Cartoni, D., Santopadre, P., Vullo, V., et al. (1994). Frequency of development of acute global left ventricular dysfunction in human immunodeficiency virus infection. J. Am. Coll. Cardiol. 24:1018-1024.
17. Longo-Mbenza, B., Seghers, L.V., Vita, E.K., Tonduangu, K., and Bayekula, M. (1998). Assessment of ventricular diastolic function in AIDS patients from Congo: a Doppler echocardiographic study. Heart 80:184-189.
18. Martinez-Garcia, T., Sobrino, J.M., Pujol, E., Galvez, J., Benitez, E., and Giron-Gonzalez, J.A. (2000). Ventricular mass and diastolic function in patients infected by the human immunodeficiency virus. Heart 84:620-624.
19. Becker, K., Gorlach, I., Frieling, T., and Haussinger, D. (1997). Characterization and natural course of cardiac autonomic nervous dysfunction in HIV-infected patients. AIDS 11:751-757.
20. Luginbuhl, L.M., Orav, E.J., McIntosh, K., and Lipshultz, S.E. (1993). Cardiac morbidity and related mortality in children with HIV infection. JAMA 269:2869-2875.
21. Calabrese, L.H., Proffitt, M.R., Yen-Lieberman, B., Hobbs, R.E., and Ratliff, N.B. (1987). Congestive cardiomyopathy and illness related to the acquired immunodeficiency syndrome (AIDS) associated with isolation of retrovirus from myocardium. Ann. Intern. Med. 107:691-692.
22. Lipshultz, S.E., Fox, C.H., Perez-Atayde, A.R., Sanders, S.P., Colan, S.D., McIntosh, K., et al. (1990). Identification of human immunodeficiency virus-1 RNA and DNA in the heart of a child with cardiovascular abnormalities and congenital acquired immune deficiency syndrome. Am. J. Cardiol. 66:246-250.
23. Bowles, N.B., Kearney, D.L., Ni, J., Perez-Atayde, A.R., Kline, M.W., Bricker, J.T., et al. (1999). The detection of viral genomes by polymerase chain reaction in the myocardium of pediatric patients with advanced HIV disease. J. Am. Coll. Cardiol. 34:857-865.
24. Grody, W.W., Cheng, L., and Lewis, W. (1990). Infection of the heart by the human immunodeficiency virus. Am. J. Cardiol. 66:203-206.
25. Seidman, R., Peress, N.S., and Nuovo, G.J. (1994). In situ detection of polymerase chain reaction-amplified HIV-1 nucleic acids in skeletal muscle in patients with myopathy. Mod. Pathol. 7:369-375.
26. Rebolledo, M.A., Krogstad, P., Chen, F.; Shannon, K.M., and Klitzner, T.S. (1998). Infection of human fetal cardiac myocytes by a human immunodeficiency virus-1-derived vector. Circ. Res. 83:738-742.
27. Kinter, A., Arthos, J., Cicala, C., and Fauci, A.S. (2000). Chemokines, cytokines and HIV: a complex network of interactions that influence HIV pathogenesis. Immunol. Rev. 177:88-98.
28. Damas, J.K., Gullestad, L., Ueland, T., Solum, N.O., Simonsen, S., Froland, S.S., et al. (2000). CXC-chemokines, a new group of cytokines in congestive heart failure-possible role of platelets and monocytes. Cardiovasc. Res. 45:428-436.
29. Twu, C., Liu, N.Q., Popik, W., Bukrinskly, M., Sayre, J., Roberts, J., et al. (2002). Cardiomyocytes undergo apoptosis in human immunodeficiency virus cardiomyopathy through mitochondrion- and death receptor-controlled pathways. Proc. Natl. Acad. Sci. USA 99:14386-14391.
30. Shannon, R.P. (2001). SIV cardiomyopathy in non-human primates. Trends Cardiovasc. Med. 11:242-246.
31. Kan, H., Xie, Z., and Finkel, M.S. (2000). HIV gp120 enhances NO production by cardiac myocytes through p38 MAP kinase-mediated NF-kappaB activation. Am. J. Physiol. Heart Circ. Physiol. 279:H3138-H3143.
32. Chen, F., Shannon, K., Ding, S., Silval M.E., Wetzel, G.T., Klitzner, T.S., et al. (2002). HIV type 1 glycoprotein 120 inhibits cardiac myocyte contraction. AIDS Res. Hum. Retroviruses 18:777-784.
33. Barry, W.H. (1994). Mechanisms of immune-mediated myocyte injury. Circulation 89:2421-2432.
34. Conraads, V.M., Bosnians, J.M., and Vrints, C.J. (2002). Chronic heart failure: an example of a systemic chronic inflammatory disease resulting in cachexia. Int. J. Cardiol. 85:33-49.
35. Mihm, M.J., Schanbacher, B.L., Basuray, A., Liu, C.Y., Amann, D.M., Ayers, L.W., et al. (2002). Peroxynitrite formation and cardiac oxidative injury in human AIDS-related cardiomyopathy. FASEB J. 16:A177-A177.
36. Fraternalé, A., Tonelli, A., Casabianca, A., Vallanti, G., Chiarantini, L., Schiavano, G.F., et al. (1999). Role of macrophage protection in the development of murine AIDS. J. Acquir. Immune Defic. Syndr. 21:81-89.
37. Chaves, A.A., Mihm, M.J., Schanbacher, B., Basuray, A., Liu, C.Y., Ayers, L.W., et al. (2003). Cardiomyopathy in a murine model of AIDS: evidence of reactive nitrogen species and corroboration in human HIV/AIDS cardiac tissues. Cardiovasc. Res. 60:108-118.
38. Hevel, J.M. and Marletta, M.A. (1992). Macrophage nitric oxide synthase: relationship between enzyme-bound tetrahydrobiopterin and synthase activity. Biochemistry 31:7160-7165.
39. Rosenberg, Z.F. and Fauci, A.S. (1989). Immunology of AIDS: approaches to understanding the immunopathogenesis of HIV infection. Ric. Clin. Lab. 19:189-209.
40. Moriuchi, M., Moriuchi, H., Turner, W., and Fauci, A.S. (1998). Exposure to bacterial products renders macrophages highly susceptible to T-tropic HIV-1. J. Clin. Invest. 102:1540-1550.
41. + T cells after bacterial stimulation. J. Infect. Dis. 181:2041-2044.
42. Fujioka, S., Kitaura, Y., Ukimura, A., Deguchi, H., Kawamura, K., Isomura, T., et al. (2000). Evaluation of viral infection in the myocardium of patients with idiopathic dilated cardiomyopathy. J. Am. Coll. Cardiol. 36:1920-1926.
43. Blankenberg, S., Rupprecht, H.J., Bickel, C., Espinola-Klein, C., Rippin, G., Hafner, G., et al. (2001). Cytomegalovirus infection with interleukin-6 response predicts cardiac mortality in patients with coronary artery disease. Circulation 103:2915-2921.
44. Matsumori, A., Yutani, C., Ikeda, Y., Kawai, S., and Sasayama, S. (2000). Hepatitis C virus from the hearts of patients with myocarditis and cardiomyopathy. Lab. Invest. 80:1137-1142.
45. Liu, Y., Montes, S., Zhang, D., Sepulveda, R.T., Yu, Q., Zhang, J., et al. (2002). Cocaethylene and heart disease during murine AIDS. Int. Immunopharmacol. 2:139-150.
46. Sepulveda, R.T., Jiang, S., Beischel, J., Bellamy, W.T., and Watson, R.R. (2000). Cocaine injection and coxsackie-virus B 3 infection increase heart disease during murine AIDS. J. Acquir. Immune Defic. Syndr. 25(Suppl. 1): S19-S26.
47. Kalayoglu, M.V., Libby, P., and Byrne, G.I. (2002). Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. JAMA 288:2724-2731.
48. Martinez Torres, A. and Martinez Gaensly, M. (2002). Helicobacter pylori: a new cardiovascular risk factor? Rev. Esp. Cardiol. 55:652-656.
49. Afzal, A., Keohane, M., Keeley, E., Borzak, S., Callender, C.W., and Iannuzzi, M. (2000). Myocarditis and pericarditis with tamponade associated with disseminated tuberculosis. Can. J. Cardiol. 16:519-521.
50. Manfredi, R., Costigliola, P., Ricchi, E., and Chiodo, F. (1993). Sepsis-bacteraemia and other infections due to non-opportunistic bacterial pathogens in a consecutive series of 788 patients hospitalized for HIV infection. Clin. Ter. 143:279-290.
51. Manfredi, R., Nanetti, A., Ferri, M., and Chiodo,F. (1999). HIV-associated non-mycobacterial sepsis-bacteraemia, before and during the highly active antiretroviral therapy era. AIDS 13:1274-1276.
52. Moroni, M. and Franzetti, F. (1995). Bacterial pneumonia in adult patients with HIV infection. J. Chemother. 7:292-306.
53. Hirschtick, R.E., Glassroth, J., Jordan, M.C., Wilcosky, T.C., Wallace, J.M., Kvale, P.A., et al. (1995). Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group. N. Engl. J. Med. 333:845-851.
54. Afessa, B., Morales, I., and Weaver, B. (2001). Bacteremia in hospitalized patients with human immunodeficiency virus: A prospective, cohort study. BMC Infect. Dis. 1:13.
55. Blanchard, A., Montagnier, L., and Gougeon, M.L. (1997). Influence of microbial infections on the progression of HIV disease. Trends Microbiol. 5:326-331.
56. Juffermans, N.P., Paxton, W.A., Dekkers, P.E., Verbon, A., de Jonge, E., Speelman, P., et al. (2000). Up-regulation of HIV coreceptors CXCR4 and CCR5 on CD4(+) T cells during human endotoxemia and after stimulation with (myco)bacterial antigens: the role of cytokines. Blood 96:2649-2654.
57. Franchin, G., Zybarth, G., Dai, W.W., Dubrovsky, L., Reiling, N., Schmidtmayerova, H., et al. (2000). Lipopolysaccharide inhibits HIV-1 infection of monocyte-derived macrophages through direct and sustained down-regulation of CC chemokine receptor 5. J. Immunol. 164:2592-2601.
58. Verani, A., Scarlatti, G., Comar, M., Tresoldi, E., Polo, S., Giacca, M., et al. (1997). C-C chemokines released by lipopolysaccharide (LPS)-stimulated human macrophages suppress HIV-1 infection in both macrophages and T cells. J. Exp. Med. 185:805-816.
59. Mihm, M.J., Schanbacher, B.L., Chaves, A.A., Basuray, A., and Bauer, J.A. (2002). Mechanisms of cardiac dysfunction in murine AIDS: immune cell trafficking and oxidative pathways. FASEB J. 16:A580-A581.
60. Chaves, A.A., Liu, C.Y., Hallenburg, M.A., Schanbacher, B.L., and Bauer, J.A. (2000). LPS immunostimulation enhances retrovirus related cardiac dysfunction during murine AIDS. Circulation 102:356.
61. Fauci, A.S. (1993). Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science 262:1011-1018.
62. Beckman, J.S. (1996). Oxidative damage and tyrosine nitration from peroxynitrite. Chem. Res. Toxicol. 9:836-844.
63. Squadrito, G.L. and Pryor, W.A. (1998). Oxidative chemistry of nitric oxide: the roles of superoxide, peroxynitrite, and carbon dioxide. Free Radic. Biol. Med. 25:392-403.
64. Crow, J.P. and Beckman, J.S. (1996). The importance of superoxide in nitric oxide-dependent toxicity: evidence for peroxynitrite-mediated injury. Adv. Exp. Med. Biol. 387:147-161.
65. Ischiropoulos, H. (1998). Biological tyrosine nitration: a pathophysiological function of nitric oxide and reactive oxygen species. Arch. Biochem. Biophys. 356:1-11.
66. Mihm, M.J., Coyle, C.M., Schanbacher, B.L., Weinstein, D.M., and Bauer, J.A. (2001). Peroxynitrite induced nitration and inactivation of myofibrillar creatine kinase in experimental heart failure. Cardiovasc. Res. 49:798-807.
67. Mihm, M.J., Yu, F., Carnes, C.A., Reiser, P.J., McCarthy, P.M., Van Wagoner, D.R., et al. (2001). Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 104:174-180.
68. Mihm, M.J., Yu, F., Weinstein, D.M., Reiser, P.J., and Bauer, J.A. (2002). Intracellular distribution of peroxynitrite during doxorubicin cardiomyopathy: evidence for selective impairment of myofibrillar creatine kinase. Br. J. Pharmacol. 135:581-588.
69. Wattanapitayakul, S.K. and Bauer, J.A. (2001). Oxidative pathways in cardiovascular disease: roles, mechanisms, and therapeutic implications. Pharmacol. Ther. 89:187-206.
70. Weinstein, D.M., Mihm, M.J., and Bauer, J.A. (2000). Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice. J. Pharmacol. Exp. Ther. 294:396-401.
71. Turko, I.V. and Murad, F. (2002). Protein nitration in cardiovascular diseases. Pharmacol. Rev. 54:619-634.
72. Drazen, J.M. and Curfman, G.D. (2002). Retraction: Barbaro et al. Incidence of dilated cardiomyopathy and detection of HIV in myocardial cells of HIV-positive patients. N. Engl. J. Med. 1998;339:1093-1099. N. Engl. J. Med. 347:140.
73. Drazen, J.M. and Curfman, G.D. (2002). Retraction: Barbaro et al. Incidence of dilated cardiomyopathy and detection of HIV in myocardial cells of HIV-positive patients. N. Engl. J. Med. 1998;339:1093-1099. N. Engl. J. Med. 347:140.
74. Barbaro, G., Di Lorenzo, G., Soldini, M., Giancaspro, G., Grisorio, B., Pellicelli, A., et al. (1999). Intensity of myocardial expression of inducible nitric oxide synthase influences the clinical course of human immunodeficiency virus-associated cardiomyopathy. Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS (GISCA). Circulation 100:933-939.
75. CDC. (2002). Drug associated HIV transmission continues in the United States. AIDS Surveillance Report 12.
76. Billman, G.E. (1995). Cocaine: a review of its toxic actions on cardiac function. Crit. Rev. Toxicol. 25:113-132.
77. Chakko, S. and Myerburg, R.J. (1995). Cardiac complications of cocaine abuse. Clin. Cardiol. 18:67-72.
78. Baldwin, G.C., Roth, M.D., and Tashkin, D.P. (1998). Acute and chronic effects of cocaine on the immune system and the possible link to AIDS. J. Neuroimmunol. 83:133-138.
79. Baldwin, G.C., Buckley, D.M., Roth, M.D., Kleerup, B.C., and Tashkin, D.P. (1997). Acute activation of circulating polymorphonuclear neutrophils following in vivo administration of cocaine. A potential etiology for pulmonary injury. Chest 111:698-705.
80. Mao, J.T., Zhu, L.X., Sharma, S., Chen, K., Huang, M., Santiago, S.J., et al. (1997). Cocaine inhibits human endothelial cell IL-8 production: the role of transforming growth factor-beta. Cell. Immunol. 181:38-43.
81. Palamara, A.T., Di Francesco, P., Ciriolo, M.R., Bue, C., Lafavia, E., Rotilio, G., et al. (1996). Cocaine increases Sendai virus replication in cultured epithelial cells: critical role of the intracellular redox status. Biochem. Biophys. Res. Commun. 228:579-585.
82. Zhang, L., Looney, D., Taub, D., Chang, S.L., Way, D., Witte, M.H., et al. (1998). Cocaine opens the blood-brain barrier to HIV-1 invasion. J. Neurovirol. 4:619-626.
83. Gan, X., Zhang, L., Berger, O., Stins, M.F., Way, D., Taub, D.D., et al. (1999). Cocaine enhances brain endothelial adhesion molecules and leukocyte migration. Clin. Immunol. 91:68-76.
84. Kolodgie, F.D., Virmani, R., Cornhill, J.F., Herderick, E.E., and Smialek, J. (1991). Increase in atherosclerosis and adventitial mast cells in cocaine abusers: an alternative mechanism of cocaine-associated coronary vasospasm and thrombosis. J. Am. Coll. Cardiol. 17:1553-1560.
85. Mannaioni, P.F., Di Bello, M.G., Raspanti, S., Mugnai, L., Romano, V., and Masini, E. (1996). Free radical mediated release of histamine from rat mast cells induced by drugs of abuse. Inflamm. Res. 45(Suppl. 1):S25-S26.
86. Di Bello, M.G., Masini, E., Ioannides, C., Fomusi Ndisang, J., Raspanti, S., Bani Sacchi, T., et al. (1998). Histamine release from rat mast cells induced by the metabolic activation of drugs of abuse into free radicals. Inflamm. Res. 47:122-130.
87. Lewis, W., Haase, C.P., Raidel, S.M., Russ, R.B., Sutliff, R.L., Hoit, B.D., et al. (2001). Combined antiretroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice. Lab. Invest. 81:1527-1536.
88. Lewis, W., Grupp, I.L., Grupp, G., Hoit, B., Morris, R., Samarel, A.M., et al. (2000). Cardiac dysfunction occurs in the HIV-1 transgenic mouse treated with zidovudine. Lab. Invest. 80:187-197.
89. Lipshultz, S.E., Easley, K.A., Orav, E.J., Kaplan, S., Starc, T.J., Bricker, J.T., et al. (2000). Absence of cardiac toxicity of zidovudine in infants. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection Study Group. N. Engl. J. Med. 343:759-766.
90. Lewis, W. (2001). Absence of cardiac toxicity of zidovudine in infants. N. Engl. J. Med. 344:458.
91. Acevedo, M., Sprecher, D.L., Calabrese, L., Pearce, G.L., Coyner, D.L., Halliburton, S.S., et al. (2002). Pilot study of coronary atherosclerotic risk and plaque burden in HIV patients: 'a call for cardiovascular prevention'. Atherosclerosis 163:349-354.
92. Bozzette, S.A., Ake, C.F., Tam, H.K., Chang, S.W., and Louis, T.A. (2003). Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N. Engl. J. Med. 348:702-710.
93. Stein, J.H., Klein, M.A., Bellehumeur, J.L., McBride, P.E., Wiebe, D.A., Otvos, J.D., et al. (2001). Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 104:257-262.
94. Liu, C.Y., Jones, C., Chaves, A.A., Baliga, R., Hoyt, D., and Bauer, J.A. (2000). HIV protease inhibitors promote endothelial dysfunction and oxidant formation. FASEB J. 14:1443.
95. De Ponti, F., Poluzzi, E., and Montanaro, N. (2000). QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. Eur. J. Clin. Pharmacol. 56:1-18.
96. Lee, K.L., Jim, M.H., Tang, S.C., and Tai, Y.T. (1998). QT prolongation and Torsades de Pointes associated with clarithromycin. Am. J. Med. 104:395-396.
97. Stahlmann, R. and Lode, H. (1999). Toxicity of quinolones. Drugs 58(Suppl. 2):37-42.
98. Albengres, E., Le Louet, H., and Tillement, J.P. (1998). Systemic antifungal agents. Drug interactions of clinical significance. Drug Saf. 18:83-97.
99. Girgis, I., Gualberti, J., Langan, L., Malek, S., Mustaciuolo, V., Costantino, T., et al. (1997). A prospective study of the effect of I.V. pentamidine therapy on ventricular arrhythmias and QTc prolongation in HIV-infected patients. Chest 112:646-653.
100. McDaniel, J.S., Fowlie, E., Summerville, M.B., Farber, E.W., and Cohen-Cole, S.A. (1995). An assessment of rates of psychiatric morbidity and functioning in HIV disease. Gen. Hosp. Psychiatry 17:346-352.
101. Baker, B., Dorian, P., Sandor, P., Shapiro, C., Schell, C., Mitchell, J., et al. (1997). Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. J. Clin. Psychopharmacol. 17:15-21.
102. Welch, R. and Chue, P. (2000). Antipsychotic agents and QT changes. J. Psychiatry Neurosci. 25:154-160.
103. Pai, V.B. and Nahata, M.C. (2000). Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf. 22:263-302.
104. Deyton, L.R., Walker, R.E., Kovacs, J.A., Herpin, B., Parker, M., Masur, H., et al. (1989). Reversible cardiac dysfunction associated with interferon alfa therapy in AIDS patients with Kaposi's sarcoma. N. Engl. J. Med. 321:1246-1249.
105. Kruit, W.H., Punt, K.J., Goey, S.H., de Mulder, P.M., van Hoogenhuyze, D.C., Henzen-Logmans, S.C., et al. (1994). Cardiotoxicity as a dose-limiting factor in a schedule of high dose bolus therapy with interleukin-2 and alpha-interferon. An unexpectedly frequent complication. Cancer 74:2850-2856.
106. Gallo, R.C., Sarin, P.S., Gelmann, E.P., Robert-Guroff, M., Richardson, E., Kalyanaraman, V.S., et al. (1983). Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science 220:865-867.
107. Chermann, J.C., Barre-Sinoussi, F., Dauguet, C., Brun-Vezinet, F., Rouzioux, C., Rozenbaum, W., et al. (1983). Isolation of a new retrovirus in a patient at risk for acquired immunodeficiency syndrome. Antibiot. Chemother. 32:48-53.
108. Autran, B., Gorin, I., Leibowitch, M., Laroche, L., Escande, J.P., Hewitt, J., et al. (1983). AIDS in a Haitian woman with cardiac Kaposi's sarcoma and Whipple's disease. Lancet 1:767-768.
109. Fink, L., Reichek, N., and Sutton, M.G. (1984). Cardiac abnormalities in acquired immune deficiency syndrome. Am. J. Cardiol 54:1161-1163.
110. Cohen, I.S., Anderson, D.W., Virmani, R., Reen, B.M., Macher, A.M., Sennesh, J., et al. (1986). Congestive cardiomyopathy in association with the acquired immunodeficiency syndrome. N. Engl. J. Med. 315:628-630.
111. Pezzotti, P., Napoli, P.A., Acciai, S., Boros, S., Urciuoli, R., Lazzeri, V., et al. (1999). Increasing survival time after AIDS in Italy: the role of new combination antiretroviral therapies. Tuscany AIDS Study Group. AIDS 13:249-255.
112. Cardoso, J.S., Moura, B., Martins, L., Mota-Miranda, A., Rocha Goncalves, F., and Lecour, H. (1998). Left ventricular dysfunction in human immunodeficiency virus (HIV)-infected patients. Int. J. Cardiol. 63:37-45.
113. Carr, A., Samaras, K., Burton, S., Law, M., Freund, J., Chisholm, D.J., et al. (1998). A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12:F51-F58.
114. Lipshultz, S.E., Easley, K.A., Orav, E.J., Kaplan, S., Starc, T.J., Backer, J.T., et al. (1998). Left ventricular structure and function in children infected with human immunodeficiency virus: the prospective P2C2 HIV Multicenter Study. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group. Circulation 97:1246-1256.
115. Monsuez, J.I., Dufaux, J., Vittecoq, D., and Vicaut, E. (2000). Reduced reactive hyperemia in HIV-infected patients. J. Acquir. Immune Defic. Syndr. 25:434-442.
116. Roldan, E.O., Moskowitz, L., and Hensley, G.T. (1987). Pathology of the heart in acquired immunodeficiency syndrome. Arch. Pathol. Lab. Med. 111:943-946.
117. Baroldi, G., Corallo, S., Moroni, M., Repossini, A., Mutinelli, M.R., Lazzarin, A., et al. (1988). Focal lymphocytic myocarditis in acquired immunodeficiency syndrome (AIDS): a correlative morphologic and clinical study in 26 consecutive fatal cases. J. Am. Coll. Cardiol. 12:463-469.
118. Klatt, E.G. and Meyer, P.R. (1988). Pathology of the heart in acquired immunodeficiency syndrome (AIDS). Arch. Pathol. Lab. Med. 112:114.
119. Reilly, J.M., Cunnion, R.E., Anderson, D.W., O'Leary, T.J., Simmons, J.T., Lane, H.C., et al. (1988). Frequency of myocarditis, left ventricular dysfunction and ventricular tachycardia in the acquired immune deficiency syndrome. Am. J. Cardiol. 62:789-793.
120. Lewis, W. (1989). AIDS: cardiac findings from 115 autopsies. Prog. Cardiovasc. Dis. 32:207-215.
121. Hansen, B.F. (1992). Pathology of the heart in AIDS. A study of 60 consecutive autopsies. APMIS 100:273-279.
122. Barbaro, G., Di, L.G., Grisorio, B., and Barbarini, G. (1998). Cardiac involvement in the acquired immunodeficiency syndrome: a multicenter clinical-pathological study. Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS Investigators. AIDS Res. Hum. Retroviruses 14:1071-1077.
123. Corallo, S., Mutinelli, M.R., Moroni, M., Lazzarin, A., Celano, V., Repossini, A., et al. (1988). Echocardiography detects myocardial damage in AIDS: prospective study in 102 patients. Eur. Heart J. 9:887-892.
124. van Hoeven, K.H., Segal, B., and Factor, S.M. (1990). AIDS cardiomyopathy: first rule out other myocardial risk factors. Int. J. Cardiol. 29:35-37.
125. Raffanti, S.P., Chiaramida, A.J., Sen, P., Wright, P., Middleton, J.R., and Chiaramida, S. (1988). Assessment of cardiac function in patients with the acquired immunodeficiency syndrome. Chest 93:592-594.
126. Kinney, E.L., Brafman, D., and Wright, R.J. (1989). Echocardiographic findings in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex (ARC). Cathet. Cardiovasc. Diagn. 16:182-185.
127. Levy, W.S., Simon, G.L., Rios, J.C., and Ross, A.M. (1989). Prevalence of cardiac abnormalities in human immunodeficiency virus infection. Am. J. Cardiol. 63:86-89.
128. Hecht, S.R., Berger, M., Van, T.A., and Croxson, S. (1989). Unsuspected cardiac abnormalities in the acquired immune deficiency syndrome. An echocardiographic study. Chest 96:805-808.
129. Himelman, R.B., Chung, W.S., Chernoff, D.N., Schiller, N.B., and Hollander, H. (1989). Cardiac manifestations of human immunodeficiency virus infection: a two-dimensional echocardiographic study. J. Am. Coll. Cardiol. 13:1030-1036.
130. Cegielski, J.P., Ramiya, K., Lallinger, G.J., Mtulia, I.A., and Mbaga, I.M. (1990). Pericardial disease and human immunodeficiency virus in Dar es Salaam, Tanzania. Lancet 335:209-212.
131. Blanchard, D.G., Hagenhoff, C., Chow, L.C., McCann, H.A., and Dittrich, H.C. (1991). Reversibility of cardiac abnormalities in human immunodeficiency virus (HIV)-infected individuals: a serial echocardiographic study. J. Am. Coll. Cardiol. 17:1270-1276.
132. Jacob, A.J., Sutherland, G.R., Boon, N.A., and Ludlam, C.A. (1993). Dilated cardiomyopathy in haemophiliacs infected with the human immunodeficiency virus. Scott. Med. J. 38:112-113.
133. Herskowitz, A., Vlahov, D., Willoughby, S., Chaisson, R.E., Schulman, S.P., Neumann, D.A., et al. (1993). Prevalence and incidence of left ventricular dysfunction in patients with human immunodeficiency virus infection. Am. J. Cardiol. 71:955-958.
134. Akhras, F., Dubrey, S., Gazzard, B., and Noble, M.I. (1994). Emerging patterns of heart disease in HIV infected homosexual subjects with and without opportunistic infections; a prospective colour flow Doppler echocardiographic study. Eur. Heart J. 15:68-75.
135. Herskowitz, A., Willoughby, S.B., Vlahov, D., Baughman, K.L., and Ansari, A.A. (1995). Dilated heart muscle disease associated with HIV infection. Eur. Heart J. 16(Suppl. O):50-55.
136. Hakim, J.G., Matenga, J.A., and Siziya, S. (1996). Myocardial dysfunction in human immunodeficiency virus infection: an echocardiographic study of 157 patients in hospital in Zimbabwe. Heart 76:161-165.
137. Cardoso, J.S. (1999). Cardiac involvement in human immunodeficiency virus infection. Rev. Port. Cardiol. 18:217-220.
138. Neild, P.J., Amadi, A., Ponikowski, P., Coats, A.J., and Gazzard, E.G. (2000). Cardiac autonomic dysfunction in AIDS is not secondary to heart failure. Int. J. Cardiol. 74:133-137.
139. Brinkman, K., ter Hofstede, H.J., Burger, D.M., Smeitink, J.A., and Koopmans, P.P. (1998). Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 12:1735-1744.
140. Frerichs, F.C., Dingemans, K.P., and Brinkman, K. (2002). Cardiomyopathy with mitochondrial damage associated with nucleoside reverse-transcriptase inhibitors. N. Engl. J. Med. 347:1895-1896.
141. Herskowitz, A., Willoughby, S.B., Baughman, K.L., Schulman, S.P., and Bartlett, J.D. (1992). Cardiomyopathy associated with antiretroviral therapy in patients with HIV infection: a report of six cases. Ann. Intern. Med. 116:311-313.
142. Periard, D., Telenti, A., Sudre, P., Cheseaux, J.J., Halfon, P., Reymond, M.J., et al. (1999). Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 100:700-705.
143. Moss, A.J. (1999). The QT interval and torsade de pointes. Drug Saf. 21(Suppl. 1):5-10; discussion 81-17.
144. Dorsey S.T. and Biblo, L.A. (2000). Prolonged QT interval and torsades de pointes caused by the combination of fluconazole and amitriptyline. Am. J. Emerg. Med. 18:227-229.
145. White, R.L. Jr., Schwartzentruber, D.J., Guleria, A., MacFarlane, M.P., White, D.E., Tucker, E., et al. (1994). Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma. Cancer 74:3212-3222.
146. Fantoni, M., Autore, C., and Del Borgo, C. (2001). Drugs and cardiotoxicity in HIV and AIDS. Ann. NY Acad. Sci. 946:179-199.